Trial Profile
A Phase III, Randomised, Multicenter, Parallel, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of GW433908 (1400 Mg Bid) and Nelfinavir (1250 Mg Bid) Over 48 Weeks in Antiretroviral Therapy Naive HIV-1 Infected Adults
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Fosamprenavir (Primary) ; Abacavir; Lamivudine; Nelfinavir
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Sponsors GSK
- 22 Oct 2005 New trial record.